A novel method for evaluating activity of transient receptor potential channels using a cellular dielectric spectroscopy.


Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 09 10 2019
revised: 27 01 2020
accepted: 29 01 2020
pubmed: 9 6 2020
medline: 11 8 2020
entrez: 8 6 2020
Statut: ppublish

Résumé

Cellular dielectric spectroscopy (CDS) is a novel technology enabling pharmacological evaluation of multiple receptor types with a label-free cell-based assay. We evaluated activities of a family of ligand-gated channels, transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) channels by an electrical impedance-based biosensor (CellKey™ system) using CDS. Measures of both potency (EC

Identifiants

pubmed: 32505645
pii: S1347-8613(20)30045-1
doi: 10.1016/j.jphs.2020.05.001
pii:
doi:

Substances chimiques

TRPA1 Cation Channel 0
TRPV Cation Channels 0
TRPV1 receptor 0
Transient Receptor Potential Channels 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

320-324

Informations de copyright

Copyright © 2020 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Auteurs

Kanako Miyano (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Katsuya Ohbuchi (K)

Tsumura Research Labs, Tumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan.

Yuka Sudo (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.

Kouichiro Minami (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Emergency Life-Saving Technique Academy of Tokyo (ELSTA TOKYO), Hachioji-shi, Tokyo 192-0364, Japan; Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi 329-0498, Japan.

Toru Yokoyama (T)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Emergency Life-Saving Technique Academy of Tokyo (ELSTA TOKYO), Hachioji-shi, Tokyo 192-0364, Japan; Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi 329-0498, Japan.

Masahiro Yamamoto (M)

Tsumura Research Labs, Tumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan.

Miaki Uzu (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Miki Nonaka (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Seiji Shiraishi (S)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Hiroaki Murata (H)

Department of Anesthesiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

Yoshikazu Higami (Y)

Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan; Translational Research Center, Research Institute of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan.

Yasuhito Uezono (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Translational Research Center, Research Institute of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan; Division of Supportive Care Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo 104-0045, Japan; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tokyo 104-0045, Japan; Department of Comprehensive Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan. Electronic address: yuezono@ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH